SURVODUTIDE

Chemical Makeup

• Molecular Formula: C192, H289, N47, O61
• Molecular Weight: 4231.69 g/mol2
• Synonyms: BI 456906, Survodutide, Dual Glucagon/GLP-1 Agonist3

[SURVODUTIDE] and Weight Reduction

In Phase 2 clinical trials involving participants with a BMI 27 kg/m², administration of Survodutide was observed to yield significant reductions in body mass. Studies indicate that after 46 weeks, subjects receiving the highest research dose (4.8 mg) experienced a mean body weight reduction of approximately 19%. The data suggests that the dual activation of GCGR and GLP-1R may produce superior weight loss outcomes compared to selective GLP-1R agonism alone, potentially due to the glucagon-mediated increase in energy expenditure.

[SURVODUTIDE] and Hepatic Health (MASH/NASH)

Research has heavily focused on Survodutide’s impact on metabolic dysfunction-associated steatohepatitis (MASH). In murine models and human clinical trials, the peptide has been shown to reduce liver fat content significantly. A notable Phase 2 trial reported that up to 83% of subjects treated with Survodutide achieved a statistically significant improvement in MASH without the worsening of fibrosis. It is hypothesized that the direct glucagon receptor activity in the liver contributes to lipolysis and the reduction of hepatic steatosis.

[SURVODUTIDE] and Glycemic Control

While primarily investigated for weight management and liver health, Survodutide has demonstrated effects on glucose homeostasis. Observations from clinical studies suggest that the peptide reduces HbA1c levels in a dose-dependent manner. Although the glucagon component theoretically increases hepatic glucose output, the strong GLP-1R agonism appears to counterbalance this, resulting in an overall improvement in glycemic parameters in subjects with Type 2 Diabetes.

[SURVODUTIDE] and Cardiovascular Markers

Exploratory endpoints in clinical research have noted potential improvements in cardiometabolic risk factors. Subjects administered Survodutide showed reductions in systolic and diastolic blood pressure, as well as favorable changes in lipid profiles, including decreases in triglycerides and LDL cholesterol. These effects are believed to be secondary to the substantial weight loss and improved metabolic profile induced by the peptide.

If you're not 100% satisfied within the first 30 days, just send it back to us and we'll give you a full refund.

No need to worry about the return shipping - we've got you covered!

We offer fast and reliable shipping on all orders. You can expect to receive it within 7-12 business days based on your location.

Please contact our customer service team for assistance if you have any questions or concerns about your shipment.

Side Effects:

In animal studies and clinical trials, the most frequently observed adverse events were gastrointestinal in nature.24 These included nausea, vomiting, diarrhea, and constipation. These effects were noted to be dose-dependent and typically occurred during the dose-escalation phase. Additionally, a transient increase in heart rate has been documented, which is consistent with the pharmacological profile of glucagon receptor agonists.25+1

Withdrawal:

Rapid cessation of the peptide in research subjects has been associated with weight regain, suggesting that the metabolic adaptations induced by the peptide are reversible upon discontinuation.

Research Use Only Disclaimer:

This product is sold strictly for laboratory research and development purposes.26 It is not intended for human consumption, diagnostic use, or therapeutic application. All researchers must handle this product in accordance with standard laboratory safety protocols, utilizing appropriate personal protective equipment (PPE).